Anavex is a pharmaceutical company engaged in the development of drug candidates.
Quote | Anavex Life Sciences Corp. (NASDAQ:AVXL)
Last: | $3.44 |
---|---|
Change Percent: | -0.29% |
Open: | $3.4 |
Close: | $3.44 |
High: | $3.48 |
Low: | $3.37 |
Volume: | 949,959 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Anavex Life Sciences Corp. (NASDAQ:AVXL)
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Anavex To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 28, 2024) - Faruqi & Faruqi, LLP, a leading national se...
NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Anavex Life Sciences Corporation (NASDAQ: AVXL)? Did you purchase your shares between February 1, 2022 and January 1, 2024, inclusive? Did you lose money in your in...
Message Board Posts | Anavex Life Sciences Corp. (NASDAQ:AVXL)
Subject | By | Source | When |
---|---|---|---|
$ANVS secured non-diluting funds for future trials. Class | jav0033 | investorshub | 04/28/2024 5:20:01 AM |
I'm certainly no expert, but I suspect that | skitahoe | investorshub | 04/28/2024 5:18:06 AM |
Power the Anvs board has the filings. They | tredenwater2 | investorshub | 04/28/2024 4:53:37 AM |
He said MILLIONS of pages for EMA approval | jav0033 | investorshub | 04/28/2024 3:38:01 AM |
Ugly model BTW. | jav0033 | investorshub | 04/28/2024 3:36:14 AM |
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
LOS ANGELES, April 23, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...
LOS ANGELES, April 16, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceu...